Mission Focused Team


BiomX is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectalcancer (CRC), as well as bacteria that affect the appearance of the skin. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets.

The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology.



Jonathan Solomon

CEO and Board Member

Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.

Assaf Oron


Assaf Oron has served as chief business officer since January 2017. Prior to this position, he served for over a decade at Evogene Ltd. (NYSE:EVGN), an agriculture biotechnology company which utilizes a proprietary integrated technology infrastructure to enhance seed traits underlying crop productivity.  At Evogene, he worked in various roles such as executive vice president of corporate development and executive vice president of strategy and business development. From 2004 to 2006, Mr. Oron served as CEO of ChondroSite Ltd., a biotechnology company that develops engineered tissue products in the field of orthopedics. From 1999 to 2003, Mr. Oron was a senior project manager and strategic consultant at POC Ltd., a leading Israeli management consulting company. Mr. Oron holds an M.Sc. in Biology (bioinformatics) and a B.Sc. in Chemistry and Economics, both from Tel Aviv University.

Dr. Sailaja Puttagunta M.D.


Dr. Sailaja Puttagunta, M.D., was most recently Vice President, Development at Iterum Therapeutics, a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens. Prior to Iterum, Dr. Puttagunta served as VP, Medical Affairs for Anti-infectives at Allergan from early 2015 and was the VP of Development and Medical Affairs at Durata Therapeutics, Inc. prior to its acquisition by Actavis plc. From 2006 to 2012, Dr. Puttagunta led teams within clinical development and medical affairs on various antibiotic compounds at Pfizer Inc. Dr. Puttagunta has 20 years of clinical, academic and research experience in medicine and in the sub-specialty of infectious diseases. She graduated from Gandhi Medical College in Hyderabad, India and completed her residency in Internal Medicine and a fellowship in Infectious Diseases at Yale University School of Medicine. She also holds an MS in Biochemistry from the New York University School of Medicine.

Dr. Merav Bassan, PhD


Dr. Bassan was most recently Vice President Head of Translational Sciences at Teva Pharmaceutical Industries, Inc., where she was responsible for early stages of clinical development via translation from animal data to human. Prior to this role, Dr. Bassan served as Vice President of Project Leadership at Teva Pharmaceutical, where she managed project leaders overseeing end-to-end drug development at pre-clinical, PI-III and post marketing stages in multiple therapeutic areas, such as pain, oncology, women‘s health, endocrinology, GI, biosimilars and other areas. Overall, Dr. Bassan has over 20 years of leadership experience with clinical and drug development teams in her various roles at Teva Pharmaceutical and other smaller biotech companies. Dr. Bassan is also a member of the Israeli 8400 health network, a cross-sector network of leaders actualizing the global disruptive capabilities of Israel’s HealthTech ecosystem. Dr. Bassan holds a Ph.D. in Neuroscience from the Tel-Aviv University Sackler School of Medicine and completed a post-doctoral fellowship in Neuroscience at Harvard University.


Chairman of the Board of Directors

Russell G. Greig, Ph.D.

Russell G. Greig, Ph.D. worked at GlaxoSmithKline for three decades, most recently as President of SR One, GlaxoSmithKline’s corporate venture group. Prior to joining SR One, he served as President of GlaxoSmithKline’s Pharmaceuticals International from 2003 to 2008 as well as on the GlaxoSmithKline corporate executive team. Currently, Dr. Greig serves as Chairman of Merus and MedEye Solutions in the Netherlands, eTheRNA in Belgium, Sanifit in Spain and Horama in France. He was previously Chairman of Ablynx in Belgium (acquired by Sanofi, France), Isconova in Sweden (acquired by Novavax, United States), Novagali in France (acquired by Santen, Japan) and Syntaxin in the United Kingdom (acquired by Ipsen, France), as well as board member of TiGenix in Belgium (acquired by Takeda, Japan).

Paul Sekhri

Paul Sekhri is President and Chief Executive Officer of the gene editing company eGenesis. He has served as President and Chief Executive Officer of Lycera Corp., and as Executive Vice President of Business Development and Chief Strategy Officer for Teva Pharmaceuticals. Mr. Sekhri has served as President and Chief Business Officer of ARIAD Pharmaceuticals and was Senior Vice President and Head of Global Search and Evaluation, M&A at Novartis. He also was an Operating Partner at TPG Biotech, where he oversaw the health and success of 52 companies within the TPG Biotech portfolio. Mr. Sekhri completed graduate work at the University of Maryland School of Medicine and received his B.S. from the University of Maryland, College Park.

Alan Moses

Alan Moses, M.D., was co-founder and co-director of the Clinical Investigator Training Program at Beth Israel Deaconess-Harvard Medical School-MIT. Dr. Moses served as Senior Vice President and Chief Medical Officer of the Joslin Diabetes Center in Boston. He was appointed Professor of Medicine at Harvard Medical School. Over the course of 14 years at Novo Nordisk, Dr. Moses served in multiple roles, rising to the position of Senior Vice President and Global Chief Medical Officer. During his tenure there, Dr. Moses provided medical support to regulatory filings for the approval of 11 successful Novo Nordisk products. Dr. Moses earned his M.D. from the Washington University School of Medicine in St. Louis, worked at the National Institutes of Health and completed subspecialty clinical training in Endocrinology at Tufts New England Medical Center.

Lynne Sullivan


Ms. Sullivan most recently served as Chief Financial Officer for Compass Therapeutics, LLC. Prior to Compass, Ms. Sullivan served as the Senior Vice President of Finance for Biogen, Inc., where she spearheaded Biogen’s Financial Planning & Analysis, Corporate Tax, and Corporate Finance groups, which includes ownership of long-range planning, capital allocation projects and the financial aspects of Mergers & Acquisitions/Business Development. Prior to that, Ms. Sullivan was the Vice President of Tax for Biogen, Vice President Tax for EMD Serono and the Vice President of Tax North America at Merck KgaA. Ms. Sullivan serves also on the Boards of resTORbio and Solid Biosciences.

Rob Woodman, Ph.D


Dr. Rob Woodman joined TVI in March 2018 as Senior Partner, and is based in London, UK. Prior to joining TVI, Rob was Director of Healthcare Investments at Touchstone Innovations (formerly Imperial Innovations) in London. He has led the formation of and fundraising for a number of UK biotech companies, such as Mission Therapeutics, Crescendo Biologics, Storm Therapeutics, and Enterprise Therapeutics. Rob joined Touchstone Innovations in 2012 and was previously a Principal in the life science team at Sofinnova Partners, a leading European venture capital firm. While at Sofinnova, Rob was actively involved in numerous investments throughout Europe. Rob’s experience also includes technology transfer with Cancer Research Technology (CRUK) and pharmaceutical consultancy with IMS Health. Rob holds an MSc in Biochemistry from the University of Oxford and a Ph.D. in Oncology from the University of Cambridge.

Jonas Grossman

Jonas Grossman is President of Chardan where he oversees the firm’s global capital markets initiatives including deal origination, syndication and secondary market sales and trading. Previously, Mr. Grossman worked at Ramius Capital Group, LLC, a global multi-strategy hedge fund where he served as Vice President and Head Trader from 2001 to 2003. He began his investment career in the cash equities business working at Aegis Capital Corp and Windsor Capital Advisor from 1999 to 2000. Mr. Grossman received a B.A. in Economics from Cornell University and an M.B.A. from the Leonard N. Stern School of Business at New York University. He also studied at the London School of Economics.

Gbola Amusa

Dr. Gbola Amusa is Partner, Director of Research and Head of Healthcare Research at Chardan.. Dr. Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns by creating shared value for society. Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma & Biotech Coordinator at UBS, where he oversaw 25 analysts, and ultimately finished as the #1 ranked European pharma analyst in the Institutional Investor (II) Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an Associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a Healthcare Finance & Strategy Consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on healthcare have been cited by socially responsible investing (SRI), ESG and sustainability organizations like FSG/Shared Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE with honors in biomedical engineering from Duke University, an MD from Washington University Medical School, and his MBA (GPA 4.0/4.0) from the University of Chicago, Booth School of Business.


Prof. Rotem Sorek


Prof. Sorek leads the Microbial Genomics group in the Department of Molecular Genetics at the Weizmann Institute of Science. He is a world leader in phage genomics and CRISPR research, and also develops techniques for high resolution understanding of microbial transcriptomics and metatranscriptomics. Prof. Sorek holds a Ph.D. in Human Genomics from Tel Aviv University, and in his postdoc, studied microbial metagenomics at the Lawrence Berkeley National Laboratory. Prior to joining the Weizmann Institute, Prof. Sorek headed the Genomics Research Group at Compugen (Nasdaq:CGEN). Prof. Sorek is also an author of numerous scientific publications in top-tier journals, and an inventor of more than 35 patents. He has received multiple awards, including the 2012 Rubinowitz-Grossman Prize in Microbiology, the 2013 Teva Founders Award for young scientists, and the 2014 FEBS Anniversary Prize. In 2015, Prof. Sorek was elected as a member of the European Academy of Microbiology.

Prof. Eran Elinav


Prof. Elinav is a senior scientist leading a research group in the Immunology Department at the Weizmann Institute of Science. Prof. Elinav has over 110 published articles and received several awards for his work, including the 2013 Alon Prize and the 2015 Rappaport Prize for outstanding biomedical research. Before joining the Weizmann Institute, Prof. Elinav held an independent research position at the Institute for Gastroenterology and Liver Disease at the Tel Aviv Sourasky Medical Center. Prof. Elinav completed his M.D. at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by internship, residency, clinical, and research positions at the Tel Aviv Medical Center Gastroenterology Institute. Prof. Elinav also has a Ph.D. in immunology from the Weizmann Institute of Science and served in a postdoctoral fellowship at the Yale University School of Medicine.

Prof. Timothy K. Lu


Prof. Lu is an associate professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Prof. Lu graduated with an S.B. and M.Eng. from MIT, and an M.D./Ph.D. from the Harvard-MIT Health Sciences and Technology program. He is also a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies that develop innovative diagnostic and therapeutic technologies for human health. Prof. Lu is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.


Prof. Richard A. Flavell, Ph.D


Dr. Flavell is a Sterling Professor of Immunobiology at Yale University and an Investigator at the Howard Hughes Medical Institute. He received his B.Sc. and Ph.D. from the University of Hull and performed postdoctoral work with Piet Borst and Charles Weissmann. Dr. Flavell was also first assistant professor (equivalent) at the University of Amsterdam (1974-79); head of the Laboratory of Gene Structure and Expression at the National Institute for Medical Research, Mill Hill, London (1979-82); and president and chief scientific officer of Biogen Research Corporation (1982-88). Dr. Flavell is a fellow of the Royal Society and a member of EMBO, the National Academy of Sciences, and the National Academy of Medicine. Dr. Flavell was also the founding chairman of Yale’s Department of Immunobiology, has published more than 1,000 peer reviewed papers, and is one of the world’s most cited immunologists.

Michael Koeris, Ph.D


Dr. Koeris is the co-founder and CEO of Sample6, a leading food-safety diagnostics provider using engineered bacteriophages to deliver the world’s first on-site, in-shift bacterial pathogen detection system. Dr. Koeris ideated and instantiated the company’s synthetic biology engineering platform, and protected product lines and manufacturing processes with 15+ patents and application portfolios. The company’s technology originated in Jim Collins’ Synthetic Biology laboratory at MIT and was expanded to include key new inventions enabling a first-in-class phage genome engineering patent for bacteriophages. This novel approach, using yeast-based recombineering, allows the assembly of modified genomes and the addition of modifications post-assembly in yeast. Dr. Koeris also worked at McKinsey & Company and Flagship Ventures, and in Jim Collins’ lab, focusing on bacterial resistance mechanisms, for his Ph.D. He remains a visiting scholar at MIT.

Learn More About BiomX